OnKure Therapeutics, Inc. Class A Common Stock

OKUR

OnKure Therapeutics, Inc. Class A (OKUR) is a biopharmaceutical company focused on developing innovative cancer therapies. It specializes in creating targeted treatments aimed at improving outcomes for patients with various malignancies, utilizing cutting-edge research and technology to address unmet medical needs in oncology.

$4.20 +0.10 (2.44%)
🚫 OnKure Therapeutics, Inc. Class A Common Stock does not pay dividends

Company News

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
GlobeNewswire Inc. • Onkure Therapeutics, Inc. • July 2, 2026

OnKure Therapeutics announced a virtual key opinion leader event on July 15, 2026, featuring prominent researchers to discuss the company's PI3Kα inhibitor drug candidates. The company is advancing two next-generation PI3Kα pan-mutant inhibitor programs (OKI-345 for breast cancer and OKI-355 for vascular anomalies) with plans to submit IND appl...

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
GlobeNewswire Inc. • N/A • December 10, 2024

OnKure Therapeutics announced positive preliminary data from its first-in-human trial of OKI-219, a PI3Kα inhibitor, showing good tolerability and favorable pharmacokinetics. The company plans to initiate a combination trial with fulvestrant in the second half of 2025.

Related Companies

Oklo Inc.
Oklo Inc.
OKLO
Okta, Inc. Class A Common Stock
Okta, Inc. Class A Common Stock
OKTA
The OLB Group, Inc. Common Stock
The OLB Group, Inc. Common Stock
OLB
OKYO Pharma Limited Ordinary Shares
OKYO Pharma Limited Ordinary Shares
OKYO